Diabetic Nephropathy Clinical Trial
Official title:
Effect of Dietary Glycemic Index/Load on Kidney-related Biomarkers and Inflammation in Diabetic Nephropathy Patients
Verified date | March 2015 |
Source | Isfahan University of Medical Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | Iran: Ethics Committee |
Study type | Interventional |
low GI and low GL diet have more beneficial effect for diabetic nephropath patients compared
with conventional diet.
low GL may have more favorable effect than low GI diet.
Status | Completed |
Enrollment | 90 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 30 Years to 75 Years |
Eligibility |
Inclusion Criteria: - diabetic nephropathy, medication stable Exclusion Criteria: - poor adherence of dietary recommendations, any changes in kind or dosage of medications |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Leila Azadbakht | Isfahan |
Lead Sponsor | Collaborator |
---|---|
Isfahan University of Medical Sciences |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Fasting blood sugar (FBS) and lipid profile concentrations (mg/dl) were measured using commercially available enzymatic reagents adopted to an auto-analyzer system. | baseline, wk 12 | Yes | |
Primary | Serum creatinine (and blood urea nitrogen (BUN) (mg/dL) were measured by colorimetric method and enzymatic colorimetric method using commercial assay kit. | baseline, wk 12 | Yes | |
Secondary | Serum levels of high sensitive C- reactive protein (hs-CRP) (mg/L) were quantified by using an ultrasensitive latex-enhanced immunoturbidimetric assay (Randox Laboratory Ltd., Belfast, United Kingdom). | baseline, wk 12 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04562025 -
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
|
N/A | |
Not yet recruiting |
NCT03658317 -
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
|
N/A | |
Recruiting |
NCT02501772 -
The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy
|
N/A | |
Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
Completed |
NCT02829177 -
Microalbuminuria and Allopurinol in Type 1 Diabetes
|
Phase 4 | |
Completed |
NCT02251067 -
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
|
Phase 2 | |
Completed |
NCT01440257 -
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
|
Phase 2 | |
Active, not recruiting |
NCT01273675 -
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy
|
N/A | |
Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
Completed |
NCT00317954 -
Spironolactone in Diabetic Nephropathy
|
Phase 4 | |
Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
Not yet recruiting |
NCT05061459 -
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
|
||
Completed |
NCT01935167 -
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01673204 -
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
|
Phase 4 | |
Completed |
NCT01726816 -
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
|
Phase 2 | |
Recruiting |
NCT01458158 -
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
|
N/A | |
Completed |
NCT01476501 -
Vitamin D Supplementation in Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01447147 -
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT01003236 -
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT00535925 -
Nephropathy In Type 2 Diabetes and Cardio-renal Events
|
Phase 4 |